Event set to improve support for staff mental wellbeing as one in five 'can't cope'
Free networking events aiming to improve the way employers support staff wellbeing are set to be launched in Swindon.
Swindon & Gloucestershire Mind (S&G Mind), in partnership with Swindon Borough Council and Business West, is holding a series of events for employers throughout 2025 which are focused on mental health in the workplace.
This comes as recent research suggests that almost a quarter of adults felt unable to manage their daily stress levels, and one in five workers had to take mental health leave from work.
The first event in the Swindon Mindful Employer Network series will be held at 9.30am on April 1 in the Cultural Heritage Institute on London Street.
The session will focus on stress awareness and workplace wellbeing.
Attendees are expected to gain valuable insights, hear real-world experiences, and engage in meaningful conversations designed to help businesses better support their teams and improve productivity.
Almost a quarter of adults are unable to manage their daily stress levels (Image: Getty Images/iStockphoto) 'We are thrilled to kick off this series with such a timely focus on workplace wellbeing, tackling stress, and prioritising mental health," said Yazmin Taylor, from S&G Mind.
"Staff are all organisations' most valuable asset, and providing the right support and advice on key mental health issues is crucial.
"Our speakers will share valuable knowledge and experiences, showing how addressing these issues can truly benefit businesses.
'We believe attendees will take away practical strategies to improve employee wellbeing. We're delighted to be collaborating with Swindon Borough Council and Business West on this important initiative for our local community.'
READ MORE: Swindon Serco workers strike again at Great Western Hospital
Swindon Borough Council leader Jim Robbins added: "Supporting mental health in the workplace is not just the right thing to do, it's essential for the wellbeing of our workforce and the success of local businesses.
"Employers who prioritise mental health create more resilient, engaged teams and a stronger healthier economy.
"We're pleased to be supporting these free workshops for local employers, helping them develop meaningful strategies to support their staff and promote workplace cultures.
"As we work to build a fairer Swindon, I encourage all employers in Swindon to take advantage of this opportunity to be part of the conversation on workplace wellbeing."
Flash Sale Alert!🌟Unlock unlimited local news subscribe today and save 40% off an annual subscription. Enjoy access to our ad-free mobile and tablet app, as well as the digital edition of the paper. Don't miss out – subscribe now!👉https://t.co/kH97dc35VK pic.twitter.com/1mWjviodRJ
— Swindon Advertiser (@swindonadver) March 20, 2025
To reserve a space, employers must book on Eventbrite at https://www.businesswest.co.uk/events/swindon-mindful-employer-network-april-2025
Susie Parker from Business West added: ''Workplace wellbeing is more than a priority – it's a necessity. Supporting mental health and tackling stress not only strengthens individuals but also contributes to business success.
"We're proud to join forces with Swindon Borough Council and S&G Mind to champion employee wellbeing, and to support a thriving workforce in the region."
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
ZimVie Stock Gains Following the Launch of RealGUIDE Software Suite
ZimVie Inc. ZIMV recently launched its RealGUIDE Software Suite and Implant Concierge service in Japan. The RealGUIDE platform enables streamlined workflows and enhanced treatment accuracy, while the Implant Concierge service offers personalized support to clinicians throughout the implant process. Together, these solutions aim to boost clinical efficiency and improve patient outcomes in Japan's rapidly evolving dental landscape. As ZimVie's largest market in the Asia-Pacific region, Japan represents a key growth opportunity. The launch is expected to enhance clinician access to end-to-end, vertically integrated digital workflows, reinforcing ZimVie's strategic focus on innovation and global market penetration. Following the announcement, shares of the company have gained 2.9% and closed at $9.38 on Friday. However, in the year-to-date period, ZIMV's shares have lost 32.7% against the industry's 5.9% growth. The S&P 500 increased 1.5% in the same time frame. The launch of the RealGUIDE Software Suite and Implant Concierge service in Japan positions ZimVie to capture a larger share of a high-potential market by offering advanced digital solutions that align with the global shift toward precision-driven, technology-enabled dentistry. By streamlining workflows and enhancing clinician efficiency, these tools can drive increased adoption of ZimVie implants and related products, fostering customer loyalty and recurring revenue. Over time, this strategic move could strengthen ZimVie's footprint in the APAC region, support margin expansion through high-value services, and contribute to sustainable long-term growth. Meanwhile, ZIMV currently has a market capitalization of $261.2 million. Image Source: Zacks Investment Research ZimVie's launch of the RealGUIDE Software Suite in Japan marks a major advancement in digital implantology, offering dentists a robust, cloud-based platform for precise implant planning, surgical guide design and restorative workflows. As the first fully cloud-integrated system of its kind, RealGUIDE allows clinicians to customize their digital workflows using modular components tailored to diagnostic, surgical, and restorative needs. The integration with ZimVie's Dental Technology Institute and its CAD/CAM milling capabilities ensures a seamless transition from case planning to final restoration, significantly improving treatment accuracy, reducing turnaround times, and enhancing patient care. This end-to-end digital experience is poised to streamline operations for clinics while improving efficiency, precision and cost-effectiveness. Complementing the RealGUIDE platform is the Implant Concierge service, a scalable virtual outsourcing solution that supports clinicians in planning and executing guided surgeries with minimal complexity. Designed for user-friendliness and zero upfront investment, Implant Concierge brings together a team of expert treatment planners and designers to ensure accuracy at every step. It integrates directly with dental labs to offer a smooth, fully coordinated experience from planning to final placement, especially beneficial for high-volume practices. Per a report by MarketsandMarkets, the global digital dentistry market, valued at $6.5 billion in 2022, is forecasted to grow at a robust CAGR of 10.9%, reaching $12.2 billion by 2028. The digital dentistry market is rising due to the growing demand for faster, more accurate, and patient-friendly dental procedures. Advancements in 3D imaging, CAD/CAM systems, and cloud-based software are enabling dentists to deliver personalized treatments with greater precision and efficiency. ZIMV carries a Zacks Rank #3 (Hold) at present. Some better-ranked stocks in the broader medical space that have announced quarterly results are CVS Health Corporation CVS, Integer Holdings Corporation ITGR and AngioDynamics ANGO. CVS Health, carrying a Zacks Rank of 2 (Buy), reported first-quarter 2025 adjusted earnings per share (EPS) of $2.25, beating the Zacks Consensus Estimate by 31.6%. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Revenues of $94.59 billion outpaced the consensus mark by 1.8%. CVS Health has a long-term estimated growth rate of 11.4%. Its earnings surpassed estimates in each of the trailing four quarters, with an average surprise of 18.1%. Integer Holdings reported first-quarter 2025 adjusted EPS of $1.31, beating the Zacks Consensus Estimate by 3.2%. Revenues of $437.4 million surpassed the Zacks Consensus Estimate by 1.3%. It currently sports a Zacks Rank of 1. Integer Holdings has a long-term estimated growth rate of 18.4%. ITGR's earnings surpassed estimates in three of the trailing four quarters and missed once, the average surprise being 2.8%. AngioDynamics, currently sporting a Zacks Rank #1, reported a third-quarter fiscal 2025 adjusted EPS of 3 cents against the Zacks Consensus Estimate of a 13-cent loss. Revenues of $72 million beat the Zacks Consensus Estimate by 2%. ANGO has an estimated fiscal 2026 earnings growth rate of 27.8% compared with the S&P 500 Composite's 10.5% growth. AngioDynamics' earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 70.9%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report AngioDynamics, Inc. (ANGO) : Free Stock Analysis Report CVS Health Corporation (CVS) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report ZimVie Inc. (ZIMV) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
3 Healthcare Stocks Skating on Thin Ice
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. But speed bumps such as inventory destockings have persisted in the wake of COVID-19, and over the past six months, the industry has pulled back by 12.3%. This performance was noticeably worse than the S&P 500's 1.9% fall. Investors should tread carefully as the influx of venture capital has also ushered in a new wave of competition. Taking that into account, here are three healthcare stocks we're swiping left on. Market Cap: $48.91 billion With a history dating back to 1897 and a presence in virtually every hospital around the globe, Becton Dickinson (NYSE:BDX) develops and manufactures medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions and professionals worldwide. Why Do We Think Twice About BDX? Annual sales growth of 4.1% over the last five years lagged behind its healthcare peers as its large revenue base made it difficult to generate incremental demand 10.5 percentage point decline in its free cash flow margin over the last five years reflects the company's increased investments to defend its market position Below-average returns on capital indicate management struggled to find compelling investment opportunities BD is trading at $170.95 per share, or 11.4x forward P/E. If you're considering BDX for your portfolio, see our FREE research report to learn more. Market Cap: $8.28 billion With a unique business model combining end-of-life care and household services, Chemed (NYSE:CHE) operates two distinct businesses: VITAS, which provides hospice care for terminally ill patients, and Roto-Rooter, which offers plumbing and water restoration services. Why Does CHE Fall Short? 4.6% annual revenue growth over the last five years was slower than its healthcare peers Capital intensity has ramped up over the last five years as its free cash flow margin decreased by 8.9 percentage points Waning returns on capital imply its previous profit engines are losing steam At $568.39 per share, Chemed trades at 22x forward P/E. Read our free research report to see why you should think twice about including CHE in your portfolio, it's free. Market Cap: $10.73 billion Formerly known as PerkinElmer until its rebranding in 2023, Revvity (NYSE:RVTY) provides health science technologies and services that support the complete workflow from discovery to development and diagnosis to cure. Why Is RVTY Risky? Organic sales performance over the past two years indicates the company may need to make strategic adjustments or rely on M&A to catalyze faster growth Day-to-day expenses have swelled relative to revenue over the last five years as its adjusted operating margin fell by 8.8 percentage points Eroding returns on capital suggest its historical profit centers are aging Revvity's stock price of $91.03 implies a valuation ratio of 17.6x forward P/E. Check out our free in-depth research report to learn more about why RVTY doesn't pass our bar. Donald Trump's victory in the 2024 U.S. Presidential Election sent major indices to all-time highs, but stocks have retraced as investors debate the health of the economy and the potential impact of tariffs. While this leaves much uncertainty around 2025, a few companies are poised for long-term gains regardless of the political or macroeconomic climate, like our Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025). Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today for free. Sign in to access your portfolio
Yahoo
an hour ago
- Yahoo
3 Healthcare Stocks in Hot Water
Personal health and wellness is one of the many secular tailwinds for healthcare companies. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have harmed the industry's returns - over the past six months, healthcare stocks have collectively shed 12.3%. This drawdown was noticeably worse than the S&P 500's 1.9% loss. Investors should tread carefully as the influx of venture capital has also ushered in a new wave of competition. Keeping that in mind, here are three healthcare stocks we're swiping left on. Market Cap: $12.17 billion With a network spanning 39 states and three countries, Universal Health Services (NYSE:UHS) operates acute care hospitals and behavioral health facilities across the United States, United Kingdom, and Puerto Rico. Why Are We Hesitant About UHS? Poor comparable store sales performance over the past two years indicates it's having trouble bringing new patients into its facilities Expenses have increased as a percentage of revenue over the last five years as its adjusted operating margin fell by 1.2 percentage points Free cash flow margin shrank by 3.1 percentage points over the last five years, suggesting the company is consuming more capital to stay competitive Universal Health Services's stock price of $188.81 implies a valuation ratio of 9.5x forward P/E. Dive into our free research report to see why there are better opportunities than UHS. Market Cap: $512.5 million With roots dating back to 1882 and operations spanning approximately 80 countries, Owens & Minor (NYSE:OMI) is a healthcare solutions company that manufactures medical supplies, distributes products to healthcare providers, and delivers medical equipment directly to patients. Why Does OMI Give Us Pause? Scale is a double-edged sword because it limits the company's growth potential compared to its smaller competitors, as reflected in its below-average annual revenue increases of 3.2% for the last two years Underwhelming 3.8% return on capital reflects management's difficulties in finding profitable growth opportunities, and its falling returns suggest its earlier profit pools are drying up Diminishing returns on capital from an already low starting point show that neither management's prior nor current bets are going as planned Owens & Minor is trading at $6.67 per share, or 3.7x forward P/E. If you're considering OMI for your portfolio, see our FREE research report to learn more. Market Cap: $132.8 billion With roots dating back to 1849 when two German immigrants opened a fine chemicals business in Brooklyn, Pfizer (NYSE:PFE) is a global biopharmaceutical company that discovers, develops, manufactures, and sells medicines and vaccines for a wide range of diseases and conditions. Why Are We Cautious About PFE? Core business is underperforming as its organic revenue has disappointed over the past two years, suggesting it might need acquisitions to stimulate growth Free cash flow margin shrank by 8.9 percentage points over the last five years, suggesting the company is consuming more capital to stay competitive Diminishing returns on capital suggest its earlier profit pools are drying up At $23.40 per share, Pfizer trades at 7.8x forward P/E. To fully understand why you should be careful with PFE, check out our full research report (it's free). Donald Trump's victory in the 2024 U.S. Presidential Election sent major indices to all-time highs, but stocks have retraced as investors debate the health of the economy and the potential impact of tariffs. While this leaves much uncertainty around 2025, a few companies are poised for long-term gains regardless of the political or macroeconomic climate, like our Top 6 Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025). Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today for free.
